The Archive · 2 posts
CRISM Therapeutics (CRTX) on LSE is pioneering cutting-edge therapies for a healthier future. 🌟 Innovative solutions in healthcare! 💡
CRISM Therapeutics secures MHRA approval and £2.7m funding for its Phase 2 glioblastoma trial, moving closer to patients.
Showing 1 of 2 posts
MHRA approves CRISM Therapeutics' Phase 2 trial for ChemoSeed in glioblastoma, targeting first patient dosing in early 2026 with localised chemotherapy delivery.
JoshuaSeptember 15, 2025
June 26, 2026